News

July 24, 2023

The paper highlights the potential of AI in the medicinal product lifecycle and the approach that developers should take with it.

July 24, 2023

Sanofi and Recludix Pharma’s deal centers on developing treatments for various immunological and inflammatory diseases.

July 24, 2023

WuXi STA’s new high-potency injectable line has an annual capacity of 12 million units.

July 24, 2023

Newly launched Crossbow Therapeutics will work to advance a novel class of antibody therapies for treating cancers.

July 21, 2023

Under a global license agreement, Bristol Myers Squibb and Evotec will advance the development of neurodegeneration pipeline assets.

July 21, 2023

The proposed spin-off of Sandoz into an independent entity has been approved by Novartis’ board of directors.

July 21, 2023

The partnership will see Flagship and Pfizer work to create a new pipeline of innovative medicines.

July 21, 2023

The expanded deal, now potentially worth more than $1.2 billion, will work to develop in vivo therapies, including sickle cell disease.

July 20, 2023

Novartis’ acquisition of biotech company DTx Pharma boosts its neuroscience pipeline and expands its capabilities in RNA-based therapeutics.

July 20, 2023

These recommendations will keep key antibiotics for respiratory infections available when they are needed most.